Fig. 6

Hemolysis and resistance to protease-mediated degradation of engineered peptides. a Schematic of experimental design and hemolytic assay results of Pol-CP-NH2 and derivatives, where hemolytic activity was evaluated by incubating the peptides (0.1–100 μmol L−1) with human red blood cells in PBS at room temperature for 1 h. Experiments were performed in three independent replicates. b Resistance to degradation of Pol-CP-NH2 and analogs exposed to fetal bovine serum (FBS) proteases for 6 h. Experiments were done in three independent replicates (statistical significance was determined using one-way ANOVA, *p < 0.039, error bars represent standard deviation values)